Altium Cares

???Medical research is the heartbeat of progress in healthcare.??? Every breakthrough starts with dedicated scientists, innovative ideas, and the support of those who believe in a healthier future. At Altium Cares, we fund groundbreaking translational research to accelerate medical advancements that save lives. Join us in making a difference—because the future of healthcare depends on the research we invest in today. ?? Learn more at?AltiumCares.org #AltiumCares #MedicalResearch #HealthTech #Healthcare #Innovation

??Could a tumor’s “stickiness” reveal how likely it is to spread? Researchers at UC San Diego have developed a groundbreaking device that sorts tumor cells based on how well they adhere to surfaces—offering a potential new way to predict cancer progression. Their findings suggest that weakly adherent cells may indicate a higher risk of metastasis. This could be a game-changer in personalizing breast cancer treatment, helping doctors determine which patients need aggressive intervention and which can avoid unnecessary procedures. ?? Learn more about this innovative approach to cancer detection: https://lnkd.in/egDAEXar) #CancerResearch #BreastCancer #MedicalBreakthrough #HealthcareInnovation #HealthTech

Together, we can drive life-saving medical research forward. Every contribution helps fund new treatments and brings hope to those in need. Join us in making a difference! ?? Donate today at?altiumcares.org/donate #MedicalResearch #HealthcareInnovation #ClinicalResearch #HealthTech #MedTech

Are you familiar with Lp(a)? Often referred to as 'Lp-little a,' this sticky form of cholesterol particle is the dangerous counterpart to the well-known 'bad' LDL cholesterol – impacting one in five individuals. Think of LDL cholesterol with an apolipoprotein(a) molecule attached, making it even more prone to forming artery-clogging plaques and causing inflammation.?Elevated levels of Lp(a) can double or triple the risk of heart attacks and increase the likelihood of strokes. Why we should be concerned is that standard cholesterol tests don't detect Lp(a), and until recently, doctors did not routinely screen for it due to the lack of available treatments.?And unfortunately, neither diet nor exercise mitigates it – it's entirely determined by your genetics. However, change is on the horizon.?There are five drugs currently in development or clinical trial phase.?One Phase II trial initiated in March 2024 by Eli Lilly and Company and Cleveland Clinic examines Muvalaplin, a potential first-of-its-kind oral rather than injectable treatment.?This extensive study involving 12,500 participants offers hope to millions with genetically high Lp(a) levels.?Developed through a collaborative effort between Monash University in Australia and Cleveland Clinic, this breakthrough therapy may not only address cardiovascular risk but also has the potential to treat other vascular diseases. The market potential for an Lp(a) therapy is considerable.?The global cholesterol-lowering drugs market, valued at USD 31.4 billion in 2022, is projected to reach USD 42.5 billion by 2031 (Transparency Market Research).?An effective oral Lp(a) treatment can potentially transform the landscape of cardiovascular care and significantly affect patient outcomes. #LipoproteinA #HeartHealth #CardiovascularRisk #Cholesterol #MedicalBreakthrough #ClinicalTrials #PharmaceuticalResearch #HealthcareInnovation

Researchers have created a skin-like hydrogel that self-heals—restoring 90% of its structure in just 4 hours and fully repairing itself in 24 hours! ?? This breakthrough could revolutionize wound healing, drug delivery, artificial skin, soft robotics, and wearable sensors! Curious how it works? ??Read more here: https://lnkd.in/etkZX5jw #Innovation #HealthTech #Biotech #ScienceNews #FutureOfMedicine

Feeling exhausted even after rest??Cancer-related fatigue is more than just being tired—it’s a persistent exhaustion that can impact daily life. Unlike regular fatigue, it doesn’t always improve with sleep and can be caused by the disease itself or its treatments. Understanding the causes and finding ways to manage fatigue can make a big difference. ?? Learn more about symptoms, causes, and ways to cope in this article:?https://lnkd.in/eaCZqwkM #Cancer #HealthAndWellness #CancerSupport #HealthTech #MedicalResearch

Did you know colorectal cancer is the second leading cause of cancer-related deaths in the U.S.? The good news—it’s preventable and treatable when caught early! Regular screenings, a healthy diet, and an active lifestyle can help lower your risk. ?? Don’t wait—take charge of your health today! Talk to your doctor about screening options and share this to spread awareness. ?? Learn more:?https://lnkd.in/e84Zq25i #ColorectalCancer #CancerResearch #PreventionIsKey #Lifestyle #MedTech

?????????? ???? ???????????????? ???????????????????? ???????????? ?????????????????? ??????????—a time to spread the word about screening for colorectal cancer. Despite being preventable through testing, colorectal cancer is the third leading global cancer, largely due to screening hesitancy or availability.?While 71.8% of U.S. adults aged 50-75 get tested, the remainder would likely be more open to less invasive options. The good news is that colorectal cancer screening and care are rapidly evolving.?Several pioneering companies are driving innovations in testing and treatment: Guardant Health’s (Nasdaq: GH) Medicare-approved Shield? blood test detects DNA shed by tumors into the bloodstream.?The 2024 NEJM-published results showed 83% sensitivity in the detection of cancer cells.?This simple blood test is an important primary screening option. Mainz Biomed (Nasdaq: MYNZ) partnering with Quest Diagnostics advances ColoAlert, a stool-based DNA test using polymerase chain reaction technology to find genetic mutations for early-stage cancer diagnosis. Ethicon, Inc., a Johnson & Johnson company, designs specialty instruments to help reduce the risk of post-surgical complications. Mayo Clinic (News Network, Jan 2025) researchers are working on combining antibody-drug conjugates with proteolysis-targeting chimeras to improve drug absorption into targeted tumor cells. Early detection and treatment technologies not only improve patient outcomes but significantly reduce national healthcare costs.?For investors, the gap in colon cancer screening is estimated at a U.S. market opportunity exceeding $4.0 billion (The Business Research Company). These companies illustrate that the transformation of colorectal cancer care offers diverse investment opportunities across diagnostics, surgical technology, and therapeutics. #ColorectalCancerAwareness #HealthcareInnovation #MedTech

It’s Colorectal Cancer Awareness Month! ??? Did you know that about 1 in 25 people in the U.S. will develop colorectal cancer in their lifetime? The good news—there are steps you can take to lower your risk. Learn more from the?American Cancer Society?about six ways to protect your health:?https://lnkd.in/ggnVJ4eW #ColorectalCancer #CancerPrevention #HealthMatters #CancerResearch #MedicalResearch

March is Colorectal Cancer Awareness Month! ?? Colorectal cancer is on the rise in younger adults, yet many aren’t screened early. A new study highlights four key warning signs you shouldn’t ignore: ?? Rectal bleeding ?? Abdominal pain ?? Diarrhea ?? Iron-deficiency anemia Even one of these symptoms could double your risk of early-onset colorectal cancer. Don’t wait—talk to your doctor! Early detection saves lives. ?? Learn more: https://lnkd.in/eq3iV-wq #ColorectalCancer #GetScreened #PublicHealth #CancerResearch #CancerPrevention